Neurogene (NGNE) Return on Capital Employed (2014 - 2026)
Neurogene's (NGNE) quarterly Return on Capital Employed came in at 43.1% in Q1 2026, down 1428.0% YoY from 3.25% in Q1 2025, and down 13.36% on a QoQ basis from 38.01% in Q4 2025.
Neurogene (NGNE) Return on Capital Employed (2014 - 2026) Analysis & Trends
Neurogene (NGNE) has 13 years of Return on Capital Employed data on file, last reported at 43.1% in Q1 2026.
- Quarterly Return on Capital Employed fell 1428.0% year-over-year to 43.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.1% (down 1428.0% YoY) and the FY2025 annual result came in at 34.94%, down 365.0% from the prior year.
- Return on Capital Employed eased to 43.1% in Q1 2026, from 38.01% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.82% in Q1 2025 to a low of 60.66% in Q3 2023.
- A 5-year average of 43.17% and a median of 41.76% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 2206 bps — and 2024, when it soared 2492 bps.
- Tracing NGNE's Return on Capital Employed over 5 years: stood at 50.79% in 2022, then rose by 18 bps to 41.76% in 2023, then advanced by 16 bps to 35.19% in 2024, then retreated by 8 bps to 38.01% in 2025, then fell by 13 bps to 43.1% in 2026.
- The last three Return on Capital Employed figures came in at 43.1% (Q1 2026), 38.01% (Q4 2025), and 35.02% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | -52.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.25% |
| Mar 31, 2026 | -43.10% |
| Dec 31, 2025 | -38.01% |
| Sep 30, 2025 | -35.02% |
| Jun 30, 2025 | -32.90% |
| Mar 31, 2025 | -28.82% |
| Dec 31, 2024 | -35.19% |
| Sep 30, 2024 | -48.55% |
| Jun 30, 2024 | -39.46% |
| Mar 31, 2024 | -31.11% |
| Dec 31, 2023 | -41.76% |
| Sep 30, 2023 | -60.66% |
| Jun 30, 2023 | -55.73% |
| Mar 31, 2023 | -56.03% |
| Dec 31, 2022 | -50.79% |
| Sep 30, 2022 | -49.37% |
| Jun 30, 2022 | -46.23% |
| Mar 31, 2022 | -41.13% |
| Dec 31, 2021 | -37.71% |
| Sep 30, 2021 | -33.72% |